APOA5 Antibody

中文名稱：

APOA5兔多克隆抗體
貨號：

CSB-PA001917LA01HU
規格：

￥440
圖片：
Immunohistochemistry of paraffin-embedded human liver cancer using CSB-PA001917LA01HU at dilution of 1:100
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

產品名稱：

Rabbit anti-Homo sapiens (Human) APOA5 Polyclonal antibody
Uniprot No.：

Q6Q788
基因名：

APOA5
別名：

Apo-AV antibody; ApoA-V antibody; Apoa5 antibody; APOA5_HUMAN antibody; ApoAV antibody; Apolipoprotein A-V antibody; Apolipoprotein A5 antibody; RAP3 antibody; Regeneration associated protein 3 antibody; Regeneration-associated protein 3 antibody
宿主：

Rabbit
反應種屬：

Human
免疫原：

Recombinant Human Apolipoprotein A-V protein (260-366AA)
免疫原種屬：

Homo sapiens (Human)

標記方式：

Non-conjugated

本頁面中的產品，APOA5 Antibody (CSB-PA001917LA01HU)，的標記方式是Non-conjugated。對于APOA5 Antibody，我們還提供其他標記。見下表：

標記方式	貨號	產品名稱	應用
HRP	CSB-PA001917LB01HU	APOA5 Antibody, HRP conjugated	ELISA
FITC	CSB-PA001917LC01HU	APOA5 Antibody, FITC conjugated
Biotin	CSB-PA001917LD01HU	APOA5 Antibody, Biotin conjugated	ELISA

克隆類型：

Polyclonal
抗體亞型：

IgG
純化方式：

>95%, Protein G purified
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
產品提供形式：

Liquid
應用范圍：

ELISA, IHC

推薦稀釋比：

Application	Recommended Dilution
IHC	1:20-1:200

Protocols：

ELISA Protocol
Immunohistochemistry (IHC) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

功能：

Minor apolipoprotein mainly associated with HDL and to a lesser extent with VLDL. May also be associated with chylomicrons. Important determinant of plasma triglyceride (TG) levels by both being a potent stimulator of apo-CII lipoprotein lipase (LPL) TG hydrolysis and an inhibitor of the hepatic VLDL-TG production rate (without affecting the VLDL-apoB production rate). Activates poorly lecithin:cholesterol acyltransferase (LCAT) and does not enhance efflux of cholesterol from macrophages. Binds heparin.
基因功能參考文獻：
1. Suggest that APOA5 SNPs rs10750097(G/G), rs1263173(A/A), rs17120035(T/T), and rs662799(G/G) may be associated with NAFLD. PMID: 29735301
2. Evidence has established the association between the presence of APOA5 gene SNPs and the risk for obesity. (Review) PMID: 30053818
3. Polymorphisms of the genes MTHFR (rs1801133) and APOA5 (rs662799), as well as anemia, are independent risk factors for stroke in Mexicans, together with traditional cardiovascular risk factors such as high triglycerides and high blood pressure. PMID: 29398535
4. Different linkage disequilibrium was found betweenAPOA5 rs207560 and rs3135506 variants in Roma compared to Hungarians PMID: 28102463
5. APOA5 polymorphisms rs662799 and rs3135507, with the CC and the AA genotypes, respectively, are associated with increased levels of both high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C) in the Turkish Cypriot population. PMID: 29264753
6. rs670, rs2854116, and rs662799 single nucleotide polymorphisms of the APOA1-C3-A5 cluster are associated with ischemic stroke in the northern Chinese Han population. PMID: 28635360
7. The minor allele rs662799 in APOA5 was risk factor for coronary artery disease occurrence in the Chinese Han population. PMID: 29310573
8. Heterozygous carriers of the variants of APOA5 display more pronounced post-prandial lipemia after pure fat load than wild-type carriers. PMID: 28730827
9. Review/Meta-analysis: significant association of APOA5 rs662799 CC and APOA5 rs3135506 CG with increased risk of ischemic stroke. PMID: 28865324
10. The data clearly show that the Arg282Ser mutation in APOA5 gene determines a reduction of triglycerides, total and LDL-cholesterol and apolipoprotein A-V levels in overweight/obese children and adolescents, demonstrating that this mutation has the power to affect lipid levels already since childhood. PMID: 28927406
11. First study reporting the association of APOA5 gene variants with Metabolic Syndrome in Tunisia. This study emphasizes the role of APOA5 variants in the regulation of the triglycerides blood levels. PMID: 28624160
12. that apos involved in TG metabolism such as apoC2, C3, E, and A4 (micromolar concentration), and apoB48 and apoA5 (single-digit nanomolar concentration) can be quantified from a single digestion mixture. PMID: 24694356
13. APOA5 variants cause Hypertriglyceridemia. In high Cardiovascular risk patients APOA5 variants elevate triglyceride levels and shift the entire lipoprotein subclass distribution toward Atherogenic Dyslipidemia. PMID: 28500476
14. Triglyceride-raising variant alleles of the APOA5 encoding apo A-V, associated with clinical Cardiovascular endpoints. PMID: 28534127
15. Hypertriglyceridemic patients carrying the APOA5 -1131T>C polymorphism exhibited increased atherogenic LDL levels and arterial stiffness, probably due to an effect of the -1131T>C polymorphism on apoA5 concentrations PMID: 29211729
16. The minor alleles of rs662799 (APOA5) and rs5072 (APOA1) modulate TG levels in Mexican children PMID: 27171122
17. Rare variants in LPL and a common variant in APOA5 were more commonly found in Thai subjects with severe hypertriglyceridemia PMID: 27206937
18. Collectively, these data demonstrate that APOA5 SNP rs651821 might be an important host genetic factor in determining the abundances of the health-promoting Bifidobacterium bacteria and the taxa to which this genus belongs. PMID: 27053630
19. Data suggest that estrogen up-regulates serum concentrations of APOA5 and subsequently decreases serum triglyceride levels; APOA5 levels are higher in woman than in men, and the negative relationship between APOA5 and serum triglyceride levels is more significant in woman. PMID: 28376804
20. Methylation in exon 3 of APOA5 and epigenetic variability are associated with high circulating triacylglycerol levels. PMID: 27613158
21. the lead variant was the rs1558861 [1.99 (1.73-2.30); p = 7.37 x 10(-22) ], residing on chromosome (chr) 11 at the apolipoprotein A-I/A-5 (APOA1/APOA5) locus PMID: 27599772
22. The single nucleotide polymorphisms in lipoprotein lipase, ApoA5, and CETP were associated with serum triglycerides and HDL-cholesterol levels, but not with coronary artery disease in Pakistani population under study. PMID: 28143480
23. ur data indicate that the APOA5 rs662799 polymorphism is associated with dyslipidemia and the severity of coronary heart disease in Chinese women. PMID: 27716220
24. HBV inhibits ApoA5 expression at both the transcriptional and translational levels through its core gene PMID: 27724895
25. Compared with APOA5 c.553 GG carriers, c.553T carriers displayed an increased risk of HTG in the Asian population, with an overall random effects OR of 3.55 (95% CI: 2.46-5.13) in the dominant model.Our results suggest that APOA5 c. 553T is an independent risk factor for HTG and increased triglyceride levels in the Asian population. PMID: 27813673
26. Genetic polymorphisms of T-1131C APOA5 and ALOX5AP SG13S114 can be considered risk factors for the susceptibility to ischemic stroke in Morocco. PMID: 27350673
27. Data show that polymorphisms of rs662799 and rs2266788 in APOA5 gene, rs320 in LPL gene and rs708272 in CETP gene had significant association with the effect of the lipid-lowering therapy via atorvastatin on ischemic stroke patients. PMID: 27415775
28. In this study, we investigated the association between the ApoA5 -1131T>C and -12,238T>C polymorphic loci in Korean patients with metabolic syndrome PMID: 26760709
29. Serum triglycerides and very low-density protein levels were significantly high in children and adolescents carrying the 19WW apoa5 genotype. PMID: 27051036
30. meta-analysis provides substantial evidence that the APOA5 -1131T/C polymorphism might contribute to coronary artery disease development in the Chinese population PMID: 26505382
31. The results of our meta-analysis point to a strong link between both APOA5 -1131T>C and APOC3 -455T>C polymorphisms and an increased risk ofcoronary heart disease . PMID: 26782469
32. A potential role for APOA5 common variants and related haplotypes as risk factors for obesity. PMID: 26524954
33. APOA5 rs2075291 could play an important role in triglyceride and HDL-C level in metabolic syndrome, while the association of APOA5 rs662799 polymorphism is still under debate. PMID: 26702748
34. the TT genotype of APOA5 c.553G T may have an important role in Taiwanese patients with hypertriglyceridemia PMID: 25843152
35. APOA5 rs662799 polymorphism has interactions with the environmental factors associated with metabolic syndrome X. PMID: 26824674
36. APOA5 -1131 T > C and APOC3 -455 T > C SNPs may play potent roles in the development and progression of coronary heart disease. (Meta-analysis) PMID: 26387083
37. Single nucleotide polymorphisms (Rs651821) of APOA5 protein did not increase the risk of CHD in the Chinese population. PMID: 26397108
38. Both the case-control study and meta-analysis confirm a significant association between APOA5 rs662799 and coronary heart disease. The results suggest a male-specific association between the APOA5 rs662799 polymorphism and coronary heart disease. [meta-analysis] PMID: 26309253
39. ApoA-V in neonates was unique in its serum concentration and in the association with lipoprotein profile PMID: 26350810
40. The polymorphisms rs662799 near APOA5 and rs769450 in APOE had significant association with metabolic syndrome X and its components in Korean males. PMID: 26365620
41. Dietary fat intake modifies the effect of APOA5 and LEPR polymorphisms on serum triglycerides, cholesterol levels and obesity in young subjects. PMID: 26365669
42. No SNPs within the BUD13-APOA5 region were associated with effect on HDL-cholesterol reduction but did have an effect on triglyceride and LDL-cholesterol levels following statin therapy. PMID: 25900265
43. Our data support the hypothesis that apoA5 promotes hepatic TG storage and therefore contributes to the pathogenesis of non-alcoholic fatty liver disease PMID: 25938357
44. cross-sectional study revealed the essential roles of the polymorphisms and haplotypes of APOA5 in the dysregulations of triglyceride levels in Uyghur population, which is an admixture population of Caucasians and East Asians PMID: 25313938
45. In a dyslipemic population, genetic variants of APOA5 modulate lipoprotein subclass distributions, inducing an atherogenic profile associated with IMT defined subclinical atherosclerosis. PMID: 25770687
46. Suggest ApoA5 genetic polymorphisms are associated with susceptibility to steroid-induced osteonecrosis of femoral head in Chinese population. PMID: 25515090
47. Results show that the USF1 and APOA5 polymorphisms are associated with Familial combined hyperlipidemia and that the S19W SNP in the APOA5 gene is associated to the disease independently of total cholesterol, triglycerides and body mass index. PMID: 25308402
48. APOA5 variants were associated with dyslipidemia and obesity in Mexicans. PMID: 24886709
49. remarkable association especially between the -1131C Apo A5 variant and increased tPA levels in asymptomatic dyslipidemic patients PMID: 24815086
50. analysis of methylation patterns of the APOA1/C3/A4/A5 cluster that may be directly involved in the transcriptional regulation of this cluster, especially in liver PMID: 25463085
顯示更多

收起更多
相關疾病：

Hypertriglyceridemia, familial (FHTR); Hyperlipoproteinemia 5 (HLPP5)
亞細胞定位：

Secreted. Early endosome. Late endosome. Golgi apparatus, trans-Golgi network.
蛋白家族：

Apolipoprotein A1/A4/E family
組織特異性：

Liver and plasma.
數據庫鏈接：

HGNC: 17288

OMIM: 144650

KEGG: hsa:116519

STRING: 9606.ENSP00000227665

UniGene: Hs.283923

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human